Background
Rising drug costs are currently a major concern worldwide. Austria also has to deal with this issue. This study aims to describe the dynamics of drug expenditure in the outpatient sector since the introduction of the current reimbursement system in Austria in 2005 (at the first ATC level). Furthermore, the key factors responsible for the current rise in drug expenditures are being addressed.
Results
Due to high-priced specialty drugs, pharmaceutical expenditures in the Austrian outpatient sector have recently increased considerably. This also contributed to the fact that a mere 0.4% of prescriptions in 2014 were responsible for almost 26% of the total costs. Closer examination reveals that the current rise is strongly dominated by the new drugs to treat hepatitis C (part of group J), followed by direct oral anticoagulants (DOACs, part of group B). Second generation direct-acting antivirals (DAAs) accounted for €64m in 2014, i.e. 2.3% of the total drug spending and 42% of the total increase in drug expenditures (€152m/+5.8%) from 2013 to 2014. DOACs accounted for 16% (€24m) of this increase. In 2014, anti-TNFs were still the most cost-intensive subgroup at ATC level 4 (€164m/5.9%) and accounted for 6.4% of the total increase. In the first half of 2015 not only the cost rise itself rose to +7.7 % but also the contribution of DAAs (51%) to this increase further intensified. The growth rate of DOACs decreased to +44%, while those of antineoplastics (+11%) and anti-TNFs (+10%) increased significantly. 
Method
The observation period of the study ranged from 2005 to June 2015. All filled prescriptions of the outpatient sector that were compensated by the 19 social security sickness funds (covering more than 97% of the national population) were included into the study. The costs were calculated using the prices as stated in the Code of Reimbursement (Erstattungskodex 1 ) in euros excluding VAT. These developments, together with the ongoing weak economic growth 2 and therefore stressed health care budgets, as well as more high-priced specialty drugs in the pipeline, all pose a challenge to the Austrian social security health care system.
Conclusion

